Author: Valle-Casuso, José Carlos; Gaudaire, Delphine; Martin-Faivre, Lydie; Madeline, Anthony; Dallemagne, Patrick; Pronost, Stéphane; Munier-Lehmann, Hélène; Zientara, Stephan; Vidalain, Pierre-Olivier; Hans, Aymeric
                    Title: Replication of Equine arteritis virus is efficiently suppressed by purine and pyrimidine biosynthesis inhibitors  Cord-id: my4n0vye  Document date: 2020_4_10
                    ID: my4n0vye
                    
                    Snippet: RNA viruses are responsible for a large variety of animal infections. Equine Arteritis Virus (EAV) is a positive single-stranded RNA virus member of the family Arteriviridae from the order Nidovirales like the Coronaviridae. EAV causes respiratory and reproductive diseases in equids. Although two vaccines are available, the vaccination coverage of the equine population is largely insufficient to prevent new EAV outbreaks around the world. In this study, we present a high-throughput in vitro assa
                    
                    
                    
                     
                    
                    
                    
                    
                        
                            
                                Document: RNA viruses are responsible for a large variety of animal infections. Equine Arteritis Virus (EAV) is a positive single-stranded RNA virus member of the family Arteriviridae from the order Nidovirales like the Coronaviridae. EAV causes respiratory and reproductive diseases in equids. Although two vaccines are available, the vaccination coverage of the equine population is largely insufficient to prevent new EAV outbreaks around the world. In this study, we present a high-throughput in vitro assay suitable for testing candidate antiviral molecules on equine dermal cells infected by EAV. Using this assay, we identified three molecules that impair EAV infection in equine cells: the broad-spectrum antiviral and nucleoside analog ribavirin, and two compounds previously described as inhibitors of dihydroorotate dehydrogenase (DHODH), the fourth enzyme of the pyrimidine biosynthesis pathway. These molecules effectively suppressed cytopathic effects associated to EAV infection, and strongly inhibited viral replication and production of infectious particles. Since ribavirin is already approved in human and small animal, and that several DHODH inhibitors are in advanced clinical trials, our results open new perspectives for the management of EAV outbreaks.
 
  Search related documents: 
                                Co phrase  search for related documents- Try single phrases listed below for: 1
 
                                Co phrase  search for related documents, hyperlinks ordered by date